Matthias Muhar
matthiasmuhar.bsky.social
Matthias Muhar
@matthiasmuhar.bsky.social
Proteostasis and gene regulation research with high-throughput genetics. Incoming Group Leader at MPI-CBG.
Reposted by Matthias Muhar
When RNA Degradation 🤝 meets 🤝 Protein Degradation! tinyurl.com/E3TDMD In a collaboration of @bartellab.bsky.social and Schulman lab, we show that, in target-directed microRNA degradation (TDMD), 2-RNA-factors recruit an E3 ligase and induce the degradation of not only a protein but also RNA (1/5).
January 6, 2026 at 8:05 AM
Reposted by Matthias Muhar
Check out the newest preprint from the Schulman lab 🎊🎉

Super cool mechanism of how a metabolite regulates the stability of its own metabolizing enzyme!

Alina did it all for this project CRISPR screen ✂️, biochemistry 🧪, and cryo-EM ❄️🔬.
Congrats!
New year, new preprint! 🎊

We are excited to share our recent work on #E3 ligase regulation in #metabolism!

www.biorxiv.org/content/10.6...

#ubiquitin #targetedproteindegradation #chemicalbiology

1/6
A CK2-FBXW11 kinase-E3 ubiquitin ligase cascade is a metabolic sensor regulating Tryptophan 2,3-dioxygenase stability
Small molecules toggling the ubiquitin-proteasome system (UPS) are powerful regulators of protein degradation. Yet, mechanistic knowledge of how endogenous ligands gate UPS decisions remains rudimentary. Here, we define control of UPS access to Tryptophan-2,3-dioxygenase (TDO2), which converts the essential amino acid tryptophan (Trp) to N-formylkynurenine. When Trp concentrations are limiting, TDO2 is degraded to avert tryptophanemia. Using CRISPRi screening and biochemistry, we identify a CK2-FBXW11 kinase-E3 ligase cascade that generates and recognizes tandem TDO2 phosphodegrons when not protected by Trp. Trp binding to an exosite safeguards TDO2 from phosphorylation-dependent ubiquitylation. Effects of Trp analogs on CK2-FBXW11-dependent ubiquitylation indicated that the indole, amino, and carboxylate groups are necessary for substrate shielding. Cryo-EM reveals how these moieties order a region proximal to the phosphodegrons; without Trp, this segment is flexible, enabling phosphorylation-coupled ubiquitylation. Overall, our data uncovered an endogenous small molecule allosterically stabilizing its own metabolizing enzyme through protection from a phosphorylation-ubiquitylation cascade. ### Competing Interest Statement B.A.S. is a member of the scientific advisory boards of Proxygen and Lyterian. The other authors declare no competing interests. Max Planck Society, https://ror.org/01hhn8329 European Union, ERC AdvG, UPSmeetMet, 101098161 to BAS Boehringer Ingelheim Fonds, https://ror.org/00dkye506
www.biorxiv.org
January 13, 2026 at 2:56 PM
Reposted by Matthias Muhar
New research group leader @matthiasmuhar.bsky.social joins @mpi-cbg.de! 🥳 With his group "Functional genomics of proteome remodeling,” Matthias wants to pursue high-throughput genetic studies to understand how protein turnover is regulated. Welcome, Matthias! www.mpi-cbg.de/news-outreac...
New research group leader for functional genomics
Molecular biologist Matthias Muhar becomes part of the MPI-CBG faculty
www.mpi-cbg.de
December 11, 2025 at 2:15 PM
Reposted by Matthias Muhar
What controls expansion & contraction of DNA repeats (e.g. Huntington's)? We were thrilled to collaborate w/ the lab of Marta Olejniczak to find out. Check out the cool screen from @sebasiegner.bsky.social and @matthiasmuhar.bsky.social that reads out repeat sequence. www.biorxiv.org/content/10.1...
www.biorxiv.org
November 26, 2025 at 8:09 AM
Fascinated by protein homeostasis, stem cells and development? I am recruiting PhD candidates through the fabulous IMPRS-CellDevoSys program. This place is buzzing with great science and brilliant minds. Come join!
If you are interested in a PhD in the area of "Mechanisms of Genome Stability" and "Functional Genomics of Proteome Remodelling," apply now for a PhD @mpi-cbg.de! Overview of all participating RGLs: imprs.mpi-cbg.de/5761/researc...
October 21, 2025 at 9:45 PM
Reposted by Matthias Muhar
⚡⚡Excited to announce I'll be starting my lab at the Max Planck Institute of Molecular Genetics (@molgen.mpg.de) in Berlin in December! Leaving sunny California to join a fantastic environment with colleagues who do super cool work.
🔬🦠I'm hiring at all levels! 🔬🦠Check: www.molgen.mpg.de/fueyo-lab
October 6, 2025 at 1:46 PM
Reposted by Matthias Muhar
Are you interested in a PhD in the area of "Mechanisms of translational control during embryogenesis?" Apply now for a PhD @mpi-cbg.de! Overview of all participating RGLs: imprs.mpi-cbg.de/5761/researc...
October 2, 2025 at 2:24 PM
Reposted by Matthias Muhar
Heads up: ignore samtools dot org, similarly minimap2 dot com and likely others. It's owned by a known phishing site and while the binaries they offer look valid currently (but note they may be serving us different binaries to others), that could change.

Ie: it's not us (Samtools team)! Be warned
September 15, 2025 at 8:40 AM
Reposted by Matthias Muhar
Looks like private funders, HHMI,CZI etc., are not going to “save” US research. Europe is setting up mechanisms to attract US researchers & it may work. But, common, target junior talent, don’t shower money on superstars who will be flying professors & return to US when the science winter passes.
August 10, 2025 at 3:35 PM
Reposted by Matthias Muhar
I am super excited to announce that I will be starting my lab at the Department of Pharmacology of the University of Zurich in Switzerland next year!
July 25, 2025 at 7:48 AM
Reposted by Matthias Muhar
📢 Open Call! The Max Perutz Labs invite applications for a Tenure-Track Professorship in Mechanistic Cell and Developmental Biology. More details ➡️ tinyurl.com/3fbkp89c
July 23, 2025 at 1:14 PM
Reposted by Matthias Muhar
We’re sharing a major update to CROPseq-multi, our versatile system for CRISPR screens that is compatible with individual and combinatorial perturbations, diverse SpCas9-based technologies, and multiple high-content, single-cell readouts. www.biorxiv.org/content/10.1...
July 14, 2025 at 12:59 PM
Reposted by Matthias Muhar
Planning to apply for #research #funding from the ERC?

From the next application rounds, expect changes to the:

• proposal structure
• evaluation process
• extra funding you can request
• eligibility for Starting & Consolidator #Grants (from 2027)

More 👇 europa.eu/!RPHWvv
Changes to the 2026 and 2027 Work Programmes
With the launch of the competitions for grants under ERC Work Programme 2026 in July of this year, several changes to the submission of applications and the evaluation of proposals will apply. The mai...
europa.eu
June 2, 2025 at 10:02 AM
Reposted by Matthias Muhar
Super excited to share our latest work on deciphering the #Ubiquitin Code

“𝗨𝗯𝗶𝗥𝗘𝗔𝗗 𝗱𝗲𝗰𝗶𝗽𝗵𝗲𝗿𝘀 𝗽𝗿𝗼𝘁𝗲𝗮𝘀𝗼𝗺𝗮𝗹 𝗱𝗲𝗴𝗿𝗮𝗱𝗮𝘁𝗶𝗼𝗻 𝗰𝗼𝗱𝗲 𝗼𝗳 𝗵𝗼𝗺𝗼𝘁𝘆𝗽𝗶𝗰 𝗮𝗻𝗱 𝗯𝗿𝗮𝗻𝗰𝗵𝗲𝗱 𝗞48 𝗮𝗻𝗱 𝗞63 𝘂𝗯𝗶𝗾𝘂𝗶𝘁𝗶𝗻 𝗰𝗵𝗮𝗶𝗻𝘀”

@cp-molcell.bsky.social

1/8

www.cell.com/molecular-ce...
UbiREAD deciphers proteasomal degradation code of homotypic and branched K48 and K63 ubiquitin chains
Ubiquitin chains determine the fates of their modified proteins, including proteasomal degradation. Kiss et al. present UbiREAD, a technology to monitor cellular degradation and deubiquitination at hi...
www.cell.com
March 24, 2025 at 2:54 PM
Reposted by Matthias Muhar
We will very soon seek to fill several positions for starting Principal Investigators with highly competitive startup packages, recruiting both for AI/ML and Life Sciences. Please spread the word and help us find the best candidates. Watch this space (us) as many exciting news will be announced.
March 13, 2025 at 4:25 PM
Reposted by Matthias Muhar
🎉Super excited to share our story on how the substrate receptor FBXO31 functions as a quality control factor by recognizing amides. This has been an amazing collaboration between Bode lab and @jcornlab.bsky.social. Special shutout goes to @matthiasmuhar.bsky.social www.nature.com/articles/s41...
C-terminal amides mark proteins for degradation via SCF–FBXO31 - Nature
SCF–FBXO31 scans proteins for C-terminal amidation and marks them for subsequent proteasomal degradation.
www.nature.com
January 29, 2025 at 4:29 PM